Quarterly report · Q3
4564.TEDINET S100Q6XE
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥700m | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥335m | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | −¥905m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | −¥1.7bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | −¥929m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.7bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥912m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥2.1bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥913m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥913m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | −¥2.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥1.4bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥2.9bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥392m | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.1bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥978m | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-4.74 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.55 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-11.52 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.73 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 68.1% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.5% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 29
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥172,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥172,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥290m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥691m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥691m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥79m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥172,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥536m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥700m |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥700m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥172,000 |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | −¥615m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥282m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥337m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥329m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥8m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | −¥127m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥7m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥7m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥132,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2021-12-31 | −¥1.3bn |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥344m |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥335m |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | −¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 322
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)やまと監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)南出 浩一 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)木村 喬 | |
| Number of submission | FilingDateInstant | 1 | |
| Business revenue (5-year summary) | Prior1YTDDuration | 335214000 | JPY |
| Business revenue (5-year summary) | CurrentYTDDuration | 699689000 | JPY |
| Business revenue (5-year summary) | Prior1YearDuration | 1153663000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | -1721711000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | -928906000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | -2071783000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | -2139211000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | -913197000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | -2571541000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | -2139211000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | -913197000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | -2571541000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 2401243000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 1051988000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 1980233000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 2892205000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 1443979000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 2685199000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | -11.52 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | -4.74 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | -13.72 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.805 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.681 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.706 | |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | -4.73 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | -1.55 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 192643700 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 192643700 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 192643700 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 192643700 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 192627600 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 1926276 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 16100 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 192643700 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 1926276 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |